Integra LifeSciences (IART) Reports In-Line Q2 EPS, Revenues Miss; Boosts FY18 EPS/Revenue Mid-Point Outlooks Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. MU
4. DPZ
5. ACN
6. NAVN
7. DFTX
8. IBM
9. META
10. ENRD

Go back to Integra LifeSciences (IART) Reports In-Line Q2 EPS, Revenues Miss; Boosts FY18 EPS/Revenue Mid-Point Outlooks Below Consensus

Integra LifeSciences Reports Second Quarter 2018 Financial Results

July 25, 2018 6:00 AM EDT

Revenue Increased 29.8% to $366.2 million; Organic Revenue Increased 3.4%

 Reported EPS of $0.14; Adjusted EPS of $0.60

Raises Low-End of Full-Year Total Revenue and EPS Guidance

Successfully Exits First Wave of Codman Transition Services Agreements

PLAINSBORO, N.J., July 25, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2018.

Second Quarter 2018 Consolidated Results

Reported revenue was $366.2 million, an increase of... More